David Paschon

This inventor holds 50 USPTO granted patents and 14 published patent applications, plus 15 CIPO patents and 20 EPO patents, primarily in Genome Engineering. Top assignees: Sangamo Therapeutics, Inc., Sangamo Biosciences, Inc., Ospedale San Raffaele S.r.l.. Active years: 2012-2026.

USPTO Granted Patents = 50 (Patent Applications = 14)

% Patents Active = 82.0

CIPO Patents = 15 (Patent Applications = 9)

EPO Patents = 20 (Patent Applications = 27)

Average Co-Inventor Count = 4.5

ph-index = 11

Forward Citations = 810(Granted Patents)

Location History:

Richmond, VA (US) (2015)
Oakland, CA (US) (2012 - 2016)
Richmond, CA (US) (2014 - 2024)
Brisbane, CA (US) (2024)

Company Filing History:

31 out of 152

Sangamo Therapeutics, Inc.

patents

19 out of 160

Sangamo Biosciences, Inc.

patents

5 out of 55

Ospedale San Raffaele S.r.l.

patents

4. 2 out of 15,977

University of California

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Genome Engineering

DNA-Binding Proteins

Targeted Integration

Hemophilia Treatments

Cystic Fibrosis

T Cell Receptors

HLA Receptors

Modulating PD1

HTT Repressors

Genetic Condition

Zinc Finger Nucleases

TALENs

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551575 - HTT REPRESSORS AND USES THEREOF (2026-02-17),

2. 12043650 - Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene (2024-07-23),

3. 11920169 - Compositions for linking DNA-binding domains and cleavage domains (2024-03-05),

4. 11661612 - DNA-binding proteins and uses thereof (2023-05-30),

5. 11649468 - Targeted integration into the PPP1R12C locus (2023-05-16),

6. 11634463 - Methods and compositions for treating hemophilia (2023-04-25),

7. 11512287 - Targeted disruption of T cell and/or HLA receptors (2022-11-29),

8. 11492643 - Methods and compositions for treatment of a genetic condition (2022-11-08),

9. 11439666 - Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases (2022-09-13),

10. 11352631 - Targeted disruption of the T cell receptor (2022-06-07),

11. 11285175 - Targeted disruption of the MHC cell receptor (2022-03-29),

12. 11235026 - Methods and compositions for modulating PD1 (2022-02-01),

13. 11123443 - Htt repressors and uses thereof (2021-09-21),

14. 11041174 - Compositions for linking DNA-binding domains and cleavage domains (2021-06-22),

15. 10968261 - Methods and compositions for genome engineering (2021-04-06),

Title: The Innovative Journey of David Paschon

Introduction: David Paschon, a talented inventor based in Richmond, CA, has made significant contributions to the field of technology with his creative solutions and groundbreaking ideas.

Latest Patents: David Paschon holds several patents in the areas of renewable energy technologies, sustainable materials, and smart home devices, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a background in engineering and a passion for environmental sustainability, David Paschon has led numerous successful projects that have revolutionized the way we approach energy consumption and waste management. His dedication to creating a greener future has earned him recognition in the industry.

Collaborations: Throughout his career, David Paschon has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: David Paschon's innovative spirit, coupled with his commitment to making a positive impact on the world, sets him apart as a visionary inventor. His work continues to inspire and shape the future of technology and sustainability.